类风湿关节炎中的亚临床间质性肺病:早期识别与管理的意义
综述指出约25%的类风湿关节炎患者存在亚临床间质性肺病,部分会进展为临床ILD。年龄、男性、吸烟、RA活动度及自身抗体阳性与亚临床病变相关,MUC5B变异等生物标志物亦有提示。目前最佳治疗未知,未来需界定高危筛查人群并研究早期干预。
要点
- 约25%的RA患者存在亚临床ILD,部分可进展为临床ILD。
- 老年、男性、吸烟及RA高活动度、自身抗体阳性是风险因素。
- 亚临床RA-ILD的最佳治疗策略尚不明确。
核心结论
- 亚临床RA-ILD常见,部分患者会进展为临床ILD并增加病残率和死亡率。
- 未来研究应聚焦界定可从筛查中获益的高危人群及早期干预对疾病进展的影响。
研究设计与样本
- 综述总结了前瞻性研究关于亚临床RA-ILD的患病率、风险因素和生物标志物的证据。
主要发现
- 前瞻性研究报道约25%的RA患者存在亚临床ILD。
- 与亚临床病变相关的人口学风险因素包括年龄较大、男性和吸烟。
- RA特异性风险因素包括RA诊断时较高的C反应蛋白和红细胞沉降率、DAS28评估的RA疾病活动度以及类风湿因子和抗环瓜氨酸肽抗体阳性。
- 与亚临床病变相关的生物标志物包括MUC5B启动子变异及血清基质金属蛋白酶7、肺和活化调节趋化因子、表面活性蛋白D水平。
临床怎么用
- 对具有高龄、男性、吸烟、高疾病活动度及自身抗体阳性的RA患者应警惕亚临床ILD。
- 可关注MUC5B变异及MMP7、PARC、SP-D等生物标志物的提示意义。
- 亚临床RA-ILD的最佳治疗尚无定论,需个体化评估。
局限性
- 亚临床RA-ILD进展风险及最佳治疗策略尚不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC IMPORTANCE: Subclinical interstitial lung disease (ILD) is common in patients with rheumatoid arthritis (RA). Some patients with subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD) will progress to clinical ILD, which is associated with increased morbidity and mortality. Recently, the American College of Rheumatology and American College of Chest Physicians (CHEST) have published guidelines addressing screening for ILD in patients with RA; however, much is unknown about risk of progression or optimal treatment strategies after recognition of subclinical RA-ILD. REVIEW FINDINGS: Prospective studies have reported subclinical ILD in around 25% of patients with RA. Demographic risk factors associated with subclinical disease include older age, male sex, and smoking. RA-specific risk factors for subclinical ILD include higher C-reactive protein and erythrocyte sedimentation rate at RA diagnosis, severity of RA disease activity as measured by the Disease Activity Score 28, and rheumatoid factor and anticyclic citrullinated peptide antibody positivity. Biomarkers associated with subclinical disease include the MUC5B promoter variant and serum levels of matrix metalloproteinase 7, pulmonary and activation-regulated chemokine, and surfactant protein D. The optimal treatment approach for subclinical disease is currently unknown. SUMMARY: Future research should focus on defining high-risk populations that will benefit from screening. Furthermore, understanding disease progression in subclinical RA-ILD and the potential for early intervention to impact the development of clinically significant disease will be critical.
引用
- Ormsby AL, Matson SM, Griffith MR, et al. Subclinical Interstitial Lung Disease in Rheumatoid Arthritis: Implications for Early Detection and Management. Chest. 2025. PMID: 41354403. doi:10.1016/j.chest.2025.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。